<DOC>
	<DOC>NCT02666391</DOC>
	<brief_summary>The purpose of the present study is to evaluate the safety and exploratory efficacy of the umbilical cord mesenchymal stem cells for patients with ischemic heart diseases.</brief_summary>
	<brief_title>Safety and Exploratory Efficacy Study of UCMSCs in Patients With Ischemic Heart Disease (SEESUPIHD)</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>Clinical diagnosis of Ischemic cardiomyopathy caused by acute occlusion or severe stenosis of anterior descending artery; LVEF (left ventricular ejection fraction): 2545%; Age between 18 and 70, borh gender; Women of childbearing age agreed to take contraceptive measures during the whole study period; No psychiatric illnesses and speaking dysfunction; Informed consent. Structural heart disease, Valvular heart disease, Refractory hypertension(Unstable blood pressure control), LVEF&lt;24%; Serious primary diseases of the liver, kidney and hematopoietic system, Abnormal liver function(glutamicpyruvic transaminase(ALT), glutamicoxaloacetic transaminase (AST) is 2 times higher than the normal value), creatinine(Cr) is higher than the upper limit of the normal value; Patients suffered from severe arrhythmia; Patients suffered from stent thrombosis; Patients receiving immunosuppressive therapy; Patients have tumor or other lethal diseases (expectation of life&lt;6 months); Women who plan to be pregnant or are pregnant or nursing; Allergic constitution(Allergic to more than two kinds of drugs,food, or pollen); Other clinical trial participants within 3 months; Investigators judge other conditions not suitable for inclusion.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>